Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | NRAS G12D |
Therapy | Alpelisib + Binimetinib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS G12D | acute myeloid leukemia | sensitive | Alpelisib + Binimetinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Binimetinib (MEK162) and Alpelisib (BYL719) inhibited proliferation in a human acute myeloid leukemia (AML) cell line harboring NRAS G12D in culture, and decreased disease burden in xenograft models (PMID: 24569456). | 24569456 |
PubMed Id | Reference Title | Details |
---|---|---|
(24569456) | Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. | Full reference... |